Scienmag

NOVEMBER 16, 2020

Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. Harmston, N., Glaser, T.L. Genome Med 12, 89 (2020). Genome Med 12, 89 (2020).

In-Vivo 53

In-Vivo RNA DNA Genome 53

Drug Discovery World

JULY 18, 2023

Incorporating in vivo pooled CRISPR screens has allowed for the interrogation of thousands of genetic perturbations in cells, leading to the determination of the involvement of molecules (PTPN2, ADAR1, or DHX37) in immune checkpoint inhibitor (ICI) responsiveness and T cell activation.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

JANUARY 23, 2023

Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

NOVEMBER 13, 2023

The presentations are as follows: Fabian Schmich, PhD, Senior Data Scientist, pRED Informatics, Roche Diagnostics Deutschland, on: ‘scifAI: An explainable machine learning framework applied to functional characterisation of therapeutic antibodies’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

NOVEMBER 22, 2020

Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells. To conduct the research, the scientists used hundreds of mice with two of the most aggressive forms of cancer: glioblastoma and metastatic ovarian cancer. Photo courtesy of Science Advances.

Gene Editing 52

Gene Editing DNA Genome Genomics 52

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. This method is generally used to deliver small interfering RNA (siRNA), but it can also be used for larger oligonucleotides too. Oligonucleotide. Anti-miRNA.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Drug Discovery World

NOVEMBER 30, 2023

DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59